Followers | 839 |
Posts | 120399 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Tuesday, October 12, 2010 8:46:16 AM
[Added PFE-KG (shown in red).]
Acquired Premium Deal iHub
Company Buyer to Market Value Date Reference
GNLB GSK 465% $57M 10/08 #msg-33209281
MEMY Roche 319% $50M 11/08 #msg-33787598
KOSN BMY 233% $190M 5/08 #msg-29647147
MGRM LH 171% $155M 6/09 #msg-38960958
COLY PFE 167% $165M 11/07 #msg-24600805
NTMD Deerfield 158%‡‡‡ $36M 1/09 #msg-35132470
EYE ABT 149% **$2.8B 1/09 #msg-34762429
IOMI Intercell 147% $190M 5/08 #msg-29232165
BTRX Stiefel 136% $150M 6/08 #msg-30201906
Tepnel GPRO 126% $132M 1/09 #msg-35221710
SGXP LLY 119% $64M 7/08 #msg-30547648
ENCY PFE 118% $350M 2/08 #msg-26978155
TRCA Ipsen 104% $660M 6/08 #msg-29795183
CRY.to MDT 97% $380M 9/08 #msg-32421462
Speedel NVS 94% $880M 7/08 #msg-30588524
MNT JNJ 92% $1.1B 11/08 #msg-33879830
MEDX BMY 90% $2.1B 7/09 #msg-39801273
SIRT GSK 85% $620M 4/08 #msg-28705020
ZGEN BMY 84% $885M 9/10 #msg-54152162
CVTX GILD *‡76% $1.4B 3/09 #msg-36225695
MOVET.BR Shire 74% $560M 8/10 #msg-52918245
IDEV ENDP *†74% *†$370M 1/09 #msg-34592416
LEVP VPHM ††73% ††$510M 7/08 #msg-30704409
TARG MDCO ***72% $42M 1/09 #msg-34774402
Ventana Roche 72% $3.4B 1/08 #msg-30912677
Jerini Shire *71% $520M 7/08 #msg-30452872
APNO Cell Bio 70% $20M 9/09 #msg-43348606
AAH.AX CEPH 69% $207M 2/09 #msg-35956544
OSTE MDT 65% $123M 8/10 #msg-53410183
TLCR Grifols 64% $3.4B 6/10 #msg-50961841
FACT ABT 64% $450M 3/10 #msg-47606240
Acambis SNY 64% $550M 7/08 #msg-30990498
JAV HSP 64% $141M 4/10 #msg-48881292
SCRX Shionogi 61% $1.4B 9/08 #msg-31859174
BFRM Merz 60% $253M 1/10 #msg-45071380
ASPM COV 56% $210M 9/09 #msg-43348479
OSIP Astellas 55% $4.0B 5/10 #msg-50234451
IDMI Takeda 55% $75M 5/09 #msg-37898204
BSMD MMSI 54% $96M 5/10 #msg-50161877
ATSI MDT 54% $370M 4/10 #msg-49617936
ALO KG ‡†54% $1.6B 11/08 #msg-33763449
MEDI AZN ‡‡53% $15.2B 4/07 #msg-19020387
MLNM Takeda 53% $8.8B 4/08 #msg-28365383
TRBN EBS ***52% $97M 8/10 #msg-53271836
PCOP LGND ***52% $75M 9/08 #msg-32404474
CLZR ELOS 51% $65M 9/09 #msg-41293512
OMRI JNJ ‡*51% $465M 11/08 #msg-33762745
IMCL LLY †††51% $6.5B 10/08 #msg-32662830
MYOG GILD 50% $2.5B 10/06 #msg-13712121
MIL Merck KGaA 50%*†* $7.2B 3/10 #msg-47249493
CRGN CLDX 50% $40M 5/09 #msg-38262967
PHRM CELG 46% $2.9B 11/07 #msg-24645394
BRL TEVA 42% **$9.0B 7/08 #msg-30792830
KG PFE 40% $3.6B 10/10 #msg-55425514
MOGN Eisai 39% $3.9B 12/07 #msg-25163775
SGP MRK 34% $41B 3/09 #msg-36140327
HTRN ENDP 34% $223M 5/10 #msg-49838813
SMTS COV 32% $250M 6/10 #msg-51344183
CGPI Galderma 30% $420M 2/08 #msg-28286522
WYE PFE 29% $68B 1/09 #msg-35077617
APPX Fresenius †29% $940M 7/08 #msg-30498388
SEPR Dainippon 28% $2.6B 9/09 #msg-41143301
Zentiva SNY ‡‡26% $2.6B 9/08 #msg-32327005
NOVN Hisamitsu 22% $428M 7/09 #msg-39515681
PPCO ENDP 19% $168M 8/10 #msg-53137069
EVVV COV 19% $2.6B 6/10 #msg-50797343
ABII CELG 17% $2.9B 6/10 #msg-51844360
ACL NVS *‡‡17% *‡‡$49.7B 1/10 #msg-45072999
CGRB JNJ 16% $970M 5/09 #msg-38039851
DNA Roche 16% †*$46.8B 3/09 #msg-36224175
ARI.to Roche ‡15% $190M 7/08 #msg-30904056
SENO BCR 14% $213M 5/10 #msg-49838776
CEGE BPAX 6% $38M 6/09 #msg-39163410
MEND JNJ 6% $480M 7/10 #msg-52176337
VXGN OXGN (4%) $33M 10/09 #msg-42578130
AVGN MNOV ***(7%) $38M 8/09 #msg-40769841
VRX BVF (7%) $3.9B 6/10 #msg-51505172
PGLA Avexa ® ® 12/08 #msg-34341452
NUVO ARCA ® ® 9/08 #msg-32420015
NOVC TSPT ® ® 9/08 #msg-31869987
VSGN IPC*†† ® ® 8/09 #msg-40603745
®Reverse merger with private or non-US company.
‡Number is misleading inasmuch as Arius announced in
May 2008 that it was pursued by an unnamed suitor.
‡‡Premium relative to commencement of bidding.
‡‡‡To be liquidated by Deerfield following failed merger with
Archemix; premium relative to 11/18/08 date of Archemix deal.
‡†Based on closing price 8/21/08, the day
before KG announced initial buyout offer.
‡*Based on 11/20/08 close.
†Premium reaches 63% if earn-out met.
††Premium and deal value based on 0.45/sh of contingent payments.
†††Premium relative to 7/30/08 close, the
day before BMY announced first buyout offer.
†*Price for 44% of DNA not already owned.
*199% premium to volume-weighted
price during preceding 3 months.
**Deal value includes assumption of debt.
***Premium and deal value exclude contingent payouts.
*‡Premium relative to 1/26/09, the day
before Astellas announced $16/sh offer.
*‡‡Price includes entire deal in three stages; 17% premium is the
blended avg price of NVS’ purchases ($164) relative to ACL’s market
price 4/4/08 immediately prior to announcement of first stage of deal.
*†Premium includes estimated value of contingent
payouts, but listed deal value excludes them.
*††IntelliPharmaCeutics.
*†*Relative to MIL’s price before announcement that co. was for sale.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.